Goldman Sachs’s Clementia Pharmaceuticals Inc. CMTA Stock Holding History

Goldman Sachs’s Portfolio CMTA Stock Details CMTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-105,407	Closed	-$2.75M	–	5526
2019 Q1	$2.75M	Buy	+105,407	New	+$1.97M	﹤0.01%	3397
2018 Q4	–	Sell	-10,981	Closed	-$122K	–	5907
2018 Q3	$122K	Buy	+10,981	New	+$116K	﹤0.01%	5072

Goldman Sachs's CMTA Position: Q2 2019 in Review

Goldman Sachs sold out of Clementia Pharmaceuticals Inc. (CMTA) in Q2 2019, closing a stake of 105,407 shares — an estimated $2.75M sold.

Goldman Sachs first reported a position in CMTA in Q3 2018 and held it in 2 quarters. The position peaked at $2.75M in Q1 2019. 0 funds tracked by Wall St. Rank hold CMTA as of Q2 2019.

Goldman Sachs reported no remaining Clementia Pharmaceuticals Inc. position as of Q2 2019 after selling out during the quarter.
Goldman Sachs sold 105,407 Clementia Pharmaceuticals Inc. shares in Q2 2019, an estimated $2.75M.
Goldman Sachs first reported a position in Clementia Pharmaceuticals Inc. in Q3 2018 and held it in 2 quarters.
Goldman Sachs's Clementia Pharmaceuticals Inc. position peaked at $2.75M in Q1 2019.
0 funds tracked by Wall St. Rank held Clementia Pharmaceuticals Inc. as of Q2 2019.

Based on Goldman Sachs's 13F filing for Q2 2019, filed 14 Aug 2019.